MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock through...
$296,814K
Proceeds from issuance of
common stock via...
$22,129K
Proceeds from issuance of
common stock through...
$3,891K
Proceeds from issuance of
common stock via...
$901K
(37.98%↑ Y/Y)
Net cash provided by
financing activities
$323,735K
(49476.57%↑ Y/Y)
Net increase
(decrease) in cash, cash...
-$83,400K
(-717.09%↓ Y/Y)
Canceled cashflow
$323,735K
Proceeds from maturities
and sales of...
$118,300K
(-20.56%↓ Y/Y)
Accounts payable and
accrued expenses
$20,522K
(566.52%↑ Y/Y)
Stock compensation
expense
$9,179K
(-72.86%↓ Y/Y)
Operating lease assets and
liabilities, net
-$507K
(-109.59%↓ Y/Y)
Other liabilities
$405K
(129.33%↑ Y/Y)
Depreciation expense
$360K
(-83.71%↓ Y/Y)
Net cash (used in)
provided by investing...
-$353,026K
(-400.16%↓ Y/Y)
Canceled cashflow
$118,300K
Net cash used in
operating activities
-$54,109K
(57.88%↑ Y/Y)
Canceled cashflow
$30,973K
Purchases of investments
$471,326K
(1425.38%↑ Y/Y)
Net loss
-$83,707K
(43.23%↑ Y/Y)
Prepaid expenses and
other current assets
$751K
(142.77%↑ Y/Y)
Net amortization of
premiums and discounts on...
$624K
(-79.14%↓ Y/Y)
Back
Back
Cash Flow
Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY)
source: myfinsight.com